Oxytocin administration suppresses hypothalamic activation in response to visual food cues by van der Klaauw, Agatha et al.
1Scientific RepoRts | 7: 4266  | DOI:10.1038/s41598-017-04600-0
www.nature.com/scientificreports
Oxytocin administration 
suppresses hypothalamic activation 
in response to visual food cues
Agatha A. van der Klaauw1, Hisham Ziauddeen1,2,3, Julia M. Keogh1, Elana Henning1, Sekesai 
Dachi1, Paul C. Fletcher1,2,3 & I. Sadaf Farooqi  1
The aim of this study was to use functional neuroimaging to investigate whether oxytocin modulates 
the neural response to visual food cues in brain regions involved in the control of food intake. Twenty-
four normal weight volunteers received intranasal oxytocin (24 IU) or placebo in a double-blind, 
randomized crossover study. Measurements were made forty-five minutes after dosing. On two 
occasions, functional MRI (fMRI) scans were performed in the fasted state; the blood oxygen level-
dependent (BOLD) response to images of high-calorie foods versus low-calorie foods was measured. 
Given its critical role in eating behaviour, the primary region of interest was the hypothalamus. 
Secondary analyses examined the parabrachial nuclei and other brain regions involved in food intake 
and food reward. Intranasal oxytocin administration suppressed hypothalamic activation to images of 
high-calorie compared to low-calorie food (P = 0.0125). There was also a trend towards suppression of 
activation in the parabrachial nucleus (P = 0.0683). No effects of intranasal oxytocin were seen in reward 
circuits or on ad libitum food intake. Further characterization of the effects of oxytocin on neural circuits 
in the hypothalamus is needed to establish the utility of targeting oxytocin signalling in obesity.
Obesity is associated with significant complications including type 2 diabetes, cardiovascular disease and some 
forms of cancer. However, effective pharmacological therapies for weight loss remain limited. There has been 
recent interest in the peptide oxytocin which appears to play a role in energy homeostasis, in addition to its role in 
parturition and lactation. Centrally administered oxytocin decreases food intake in a dose-dependent manner in 
lean and obese rodents1. Additionally, targeted deletion of the oxytocin or oxytocin receptor gene in mice results 
in late onset obesity2, 3. In humans, loss of function variants of oxytocin or its receptor have not been described to 
date, but a 42% reduction in oxytocin neurons in the hypothalamus has been found in post-mortem brain studies 
of patients with Prader-Willi Syndrome, a genetic syndrome characterised by severe hyperphagia and obesity4. 
Similarly, haplo-insufficiency for SIM1, a transcription factor that is critical for the development of hypothalamic 
oxytocin neurons, is characterised by severe obesity and hyperphagia in humans5 and mice6.
Whilst there is compelling evidence for oxytocin’s role in food intake and energy homeostasis in preclinical 
models, the three human studies to date that have examined the effects of intranasal oxytocin on food intake in 
humans have shown varying results7–10. It therefore remains to be determined whether intranasal oxytocin acutely 
modulates the neural circuitry involved in the regulation of food intake in humans. We examined the effect of a 
single dose of intranasal oxytocin, compared to placebo, on the neural response to visual food cues using func-
tional magnetic resonance imaging (fMRI) in healthy lean volunteers. We used an experimental paradigm that 
has been used by ourselves and others11, to investigate the neural response to visual food cues, and its modulation 
by physiological and pharmacological manipulations12, 13. We also examined the effects of intranasal oxytocin on 
food intake.
Methods
Participants. Twenty-four healthy volunteers (n = 11 male; mean ± SD, BMI 22.3 ± 0.4 kg/m² (range 
17–25 kg/m2); age 27.1 ± 1.6 yrs (range 21–59 yrs)) were enrolled in the study after providing written informed 
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consent. The study was approved by the Cambridge South Research Ethics Committee (LREC 12/EE/0091), UK 
and conducted in accordance with the Declaration of Helsinki. Participants were required to be weight stable for 
the 3 months prior to the study. Exclusion criteria were significant medical history, pregnancy, breastfeeding, use 
of any regular medication and any contraindications to MRI scanning. If participants were suffering from hay 
fever or common cold, study visits were rescheduled as nasal inflammation may impair absorption of oxytocin.
Design. In a double-blind, randomized crossover four-period design, participants received placebo (2 treat-
ment periods) or 24 IU oxytocin (Syntocinon, Novartis, 3 sprays per nostril, 2 treatment periods). Participants 
attended for a total of 4 visits, separated by at least one week to avoid carry-over effects. Participants were 
instructed to fast overnight prior to each visit and received either placebo or oxytocin at the beginning of each 
study visit. Following this, 45 minutes later they underwent fMRI scanning on 2 visits and received an ad libitum 
breakfast on 2 visits.
Procedures. Imaging paradigm. Participants performed a simple task adapted from one reported previ-
ously11 in which they viewed and reported their subjective liking for images from four categories: high-calorie 
foods (e.g. pizza), low-calorie foods (e.g. carrots), rewarding non-food items (e.g. consumer gadgets) and less 
rewarding non-food items (e.g. paper clips). All images were matched for colour, size and background. The task 
comprised of 6 blocks of 5 images each for each category, randomly interspersed with fixation blocks. A total of 
120 images were presented, each image for 4.5 seconds (block length = 22.5 seconds). Participants were instructed 
to indicate how much they liked each image by pressing a button on the button box and were instructed that the 
duration of their button press would be taken as the measure of their liking.
Data Acquisition and Processing. fMRI data were acquired on a Siemens Verio scanner operating at 
3 Tesla with a 192 mm field of view at the Wolfson Brain Imaging Centre, Cambridge, UK. 446 gradient echo 
T2*-weighted echo planar images (EPI) were acquired for each participant. To avoid T1 equilibration effects, the 
first six images were discarded. The images comprised 31 slices, each 3 mm thick with a 0.8 mm inter-slice gap and 
a 64 × 64 data matrix. Slices were acquired in an ascending interleaved fashion with a repetition time = 2000 ms, 
an echo time = 30 ms, flip angle = 78°, axial orientation = oblique. Data were analysed using the SPM8 program 
(www.fil.ion.ucl.ac.uk) for statistical parametric mapping. Images were realigned to the mean image and then 
spatially normalised to a standard template. As the hypothalamus was the defined region of interest (ROI) the 
data were spatially smoothed with an isotropic 4 mm full width at half maximum 3 dimensional Gaussian kernel. 
The time series in each session were high-pass filtered (with cut-off frequency 1/120 Hz) and serial autocorrela-
tions were estimated using an AR (1) model.
Imaging Analysis. The four experimental categories were modelled using a box car function convolved with 
a canonical haemodynamic response. The first level models included temporal derivatives for each condition, a 
regressor that contained the mean button press duration for the block, and the motion realignment parameters. 
The beta parameter estimated at each voxel in the general linear model for each stimulus type was derived from 
the mean least-squares fit of the model to the data. The contrast of interest was the comparison of high-calorie 
to low-calorie foods. The primary region of interest (ROI) was the hypothalamus and the following exploratory 
ROIs were also examined: the parabrachial nuclei, ventral striatum, amygdala, caudate and putamen bilaterally, 
and the midbrain. The hypothalamus, amygdala, caudate and putamen ROIs were generated using the PickAtlas 
tool in SPM8. As the hypothalamus ROI is small, we overlaid the hypothalamus ROI on the mean structural 
image from all 24 subjects (left) panel and on the SPM template mean structural image and found that the ROI 
defined in PickAtlas fitted the data. The parabrachial nuclei were defined as 5 mm spheres centred on −8, −36, 
−26 (left PBN) and 6, −36, −22 (right PBN)14. The ventral striatum and midbrain masks were defined based 
on previously published anatomical masks15. In case of bilateral ROIs we did not pool the left and right ROIs. 
The average parameter estimate for all voxels within the mask were extracted from all ROIs separately using 
MARSBAR. After unblinding the data, 17 participants had received placebo, and 7 had received oxytocin at their 
first visit. Therefore a visit factor was included in all analysis models. The extracted parameter estimates were 
examined using a mixed-effect model in R (nlme) with subject as a random effect, and treatment condition and 
visit as fixed effects. In addition to the ROI analysis, an exploratory whole brain analysis was carried out at a sta-
tistical threshold of p < 0.05, family-wise error corrected.
Food intake study. An ad libitum breakfast meal paradigm was used to measure food intake. Two nutri-
tionally balanced (30% fat, 20% protein and 50% carbohydrate energy content) foods familiar to British people 
were provided in excess (14.4 MJ/3352 Kcal). Volunteers were instructed to eat until comfortably full and food 
was covertly weighed before and after consumption. Participants were given various computer tasks and ques-
tionnaires between dosing and food intake and were instructed that these were the primary outcome measures to 
avoid awareness of monitoring food intake as this might have influenced their behaviour. Food intake was exam-
ined using mixed effect models in R; p < 0.05 was deemed to be statistically significant. Visit order was included 
in all models.
Results
All 24 participants completed the both neuroimaging visits and 23 completed both food intake visits, one partic-
ipant only attended one food intake visit. In the primary ROI analysis of the hypothalamus, the BOLD response 
to high-calorie vs low-calorie food images, was significantly attenuated with oxytocin compared to placebo 
(T = −2.72, df = 22, p = 0.0125, Fig. 1). In addition, we found a trend towards a suppressive effect of oxytocin 
in the right parabrachial nucleus (PBN) (T = −1.92, df = 22, p = 0.0683, Fig. 1). There were no effects of oxy-
tocin seen in the ventral striatum, amygdala, caudate, putamen or midbrain (Supplementary Figure 1). No other 
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regional differences were found in the exploratory whole brain analysis. We explored the food vs non-food con-
trast in the primary and exploratory ROIs; these effects were not significant (Supplementary Figure 2). There were 
no differences between males and females (data not shown).
Although we observed that liking ratings were greater for high calorie rather than low calorie food images 
(Fig. 2), there was no difference in subjective liking measures for any of the image categories between the placebo 
and oxytocin conditions (Fig. 2). Additionally, energy intake at an ad libitum test meal was comparable in the 
placebo (745 ± 73 kcal) and oxytocin (761 ± 53 kcal) treatments. There were no significant correlations between 
the degree of hypothalamic suppression on oxytocin and food intake with placebo or oxytocin.
Discussion
Here we show that intranasal oxytocin modulates hypothalamic activation to visual food cues in humans. Neural 
activation (increase in the BOLD signal) by images of high calorie compared to low calorie foods may be a proxy 
for the brain response to hunger or for increased salience of more rewarding food stimuli in the hungry state, 
based on previous studies in states of complete leptin deficiency11. We showed that oxytocin administration sup-
presses BOLD activation by images of high calorie compared to low calorie foods in the hypothalamus. This 
suggests that oxytocin directly/indirectly modulates neural circuits within the hypothalamus that are normally 
activated by images of high calorie compared to low calorie foods (ie: by hunger). These findings are intrigu-
ing and warrant replication in larger studies of lean and obese people. As changes in hypothalamic activation 
as visualised by fMRI have been shown to correlate with the anorectic effects of anti-obesity drugs such as 
sibutramine13 and exenatide16 these findings suggest that further exploration of therapeutic agents which might 
engage these neural circuits sufficiently to affect food intake is warranted.
We did not find an effect of oxytocin on ad libitum food intake in our paradigm in line with a study in 20 
healthy lean men9, but in contrast with a recent study of lean and obese men8. Potential explanations are the 
Figure 1. Hypothalamic and parabrachial nuclei (PBN) response to oxytocin. A: (A) Examination of the 
contrast of high calorie versus low calorie foods within the hypothalamus across all datasets (N = 48). The 
statistical parametric map is overlaid on the SPM8 T1 template image and thresholded at p < 0.05 uncorrected 
for display purposes. After small volume correction, one voxel −8, −6, −8 survives at p = 0.0125. (B) Parameter 
estimates extracted from the hypothalamus ROIs showing a significant decrease in the parameter estimate 
in the oxytocin (OXT) condition compared to placebo (PBO). B: (A) Examination of the contrast of high 
calorie versus low calorie foods within the PBN across all datasets (N = 48). Image is thresholded at p < 0.05 
uncorrected for display purposes. (B) Parameter estimates extracted from the PBN ROIs showing a trend 
towards decrease in the parameter estimate in the right PBN in the oxytocin condition (p = 0.0683).
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inclusion of lean and obese people in the latter study or the timing of the test meal (45 minutes in the studies that 
did not show effect on breakfast intake and 60 minutes in the study that did). Indeed, Ott et al. did find a decrease 
in snacking throughout the morning after oxytocin administration9. Additionally, one perturbation in the com-
plex neural circuitry controlling eating behaviour (ie: reduced activation of a set of circuits in the hypothalamus) 
may not be sufficient to generate an anorectic effect that could be detected within the constraints of our food 
intake test.
The neural circuits that convey the anorectic effects of oxytocin involve areas with high oxytocin receptor 
expression such as the ventromedial hypothalamus, the ventral tegmental area, the nucleus accumbens and amyg-
dala. Interestingly, a recent study by Striepens et al. found that intranasal oxytocin enhanced cognitive control in a 
food craving task alongside neural activation of prefrontal cortical areas involved in inhibitory control17.
There are some limitations with our study design. Having participants return for four visits may have had an 
impact on their behavior through familiarity with the experimental paradigm. We did include a visit effect in all 
the models to account for the repeated within-subject testing. This was however done separately for the fMRI and 
food intake sessions.
Whilst intranasal administration was directly supervised in all cases, there is no straightforward way of 
measuring uptake of intranasally administered drugs. There are inherent challenges in assessing the central 
bio-availability of oxytocin following intranasal administration18. Although small increases in CSF levels of oxy-
tocin (from 20 to 30 pM) have been measured after intranasal administration in humans17, central availability is 
likely to vary greatly between and within individuals. Indeed, a recent study has suggested that oxytocin might 
be more effective at suppressing food intake in obese compared to lean participants10. The latter findings are sup-
ported by rodent studies where weight loss is more pronounced in diet-induced obese (DIO) animals compared 
to lean controls19 following oxytocin administration. Interestingly, a small prospective study with obese men and 
women found small effects on body weight during 8 week treatment with four times daily intranasal oxytocin7. 
Our human studies suggest that, as identified in the autism field20, dose and duration of effect (and thus timing of 
any physiological measurement) are important issues when considering oxytocin as a potential therapeutic. It is 
plausible that repeated dosing may increase central bioavailability, but this requires replication.
In conclusion, we have demonstrated that intranasal oxytocin modulates hypothalamic activation to visual 
food cues in humans. These findings suggest that oxytocin responsive neural circuits contribute to the hypotha-
lamic response to visual food cues. Further characterisation of these neural circuits will be needed to determine 
whether modulation of oxytocin-mediated signalling may be of benefit in the treatment of disorders of energy 
homeostasis such as obesity.
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